Petrovax Pharm participates in the Russia–Vietnam business meeting

On September 12, Petrovax Pharm participated in a business dialogue between Russian and Vietnamese pharmaceutical companies, held as part of the official visit of Mikhail Murashko, Minister of Health of the Russian Federation, to Vietnam.

The meeting took place in Hanoi and brought together key representatives of the healthcare sectors of both countries — including Ministers of Health Mikhail Murashko and Dao Hong Lan, heads of leading medical universities and research institutes, representatives of pharmaceutical companies, as well as officials from the Russian Trade Mission and the Ministry of Industry and Trade of Russia.

The Ministers emphasized the importance of fostering direct contacts between enterprises of the two countries and promoting the exchange of experience among research, manufacturing, and healthcare institutions. The parties discussed opportunities for expanding cooperation, including the supply of medical products and joint research initiatives.

During the event, Ilya Sokolov, Head of Export at Petrovax Pharm, presented the company’s product portfolio and strategic development priorities, highlighting the company’s achievements in export growth and the expansion of its hospital portfolio.

In addition, Petrovax representatives held meetings with leading Vietnamese distributors and regulatory authorities. The discussions focused on strengthening partnerships and exploring opportunities to expand the company’s presence in the Vietnamese market.

"This forum can serve as a foundation for launching and developing Petrovax Pharm’s business in Vietnam. We see significant potential for expanding the availability of our medicines in this country and are ready for long-term, mutually beneficial cooperation,"
said Ilya Sokolov.

Petrovax Pharm is one of Russia’s leading exporters of original medicines and vaccines. In 2024, the company’s export volume reached RUB 2.3 billion, and in 2025 it expects to exceed RUB 3 billion. The company continues to consistently expand its international footprint, particularly across the Southeast Asian markets, while strengthening its position in the global pharmaceutical arena.

Previous news

Experts discussed ways to improve access to innovative medicines for Russian patients